**Amendments to the Claims**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims**

Claims 1-22 (canceled)

Claim 23 (new): A method of reducing HIV-1 viral load in an HIV-1 infected subject which comprises administering to the subject solely after viral steady state is reached an effective viral load reducing amount of an antibody which (a) binds to a CCR5 chemokine receptor and (b) inhibits fusion of HIV-1 to a CD4+CCR5+ cell, so as to thereby reduce the subject's HIV-1 viral load to 50% or less of the subject's viral load prior to any administration of the antibody to the subject.

Claim 24 (new): A method of reducing HIV-1 viral load in an HIV-1 infected subject which comprises administering to the subject an effective viral load reducing amount of an antibody which (a) binds to a CCR5 chemokine receptor, (b) inhibits fusion of HIV-1 to a CD4+CCR5+ cell, and (c) inhibits binding of HIV-$1_{JR-FL}$ gp120 to the CCR5 receptor, so as to thereby reduce the subject's HIV-1 viral load to 50% or less of the subject's HIV-1 viral load prior to any administration of the antibody to the subject.

Claim 25 (new): The method of claim 23 or claim 24, wherein the antibody is a monoclonal antibody.

Claim 26 (new): The method of claim 23 or claim 24, wherein the antibody is selected from the group consisting of PA8 (ATCC

Accession No. HB-12605), PA9 (ATCC Accession No. HB-12606), PA10 (ATCC Accession No. HB-12607), PA11 (ATCC Accession No. HB-12608), PA12 (ATCC Accession No. HB-12609) and PA14 (ATCC Accession No. HB-12610).

Claim 27 (new): The method of claim 23 or claim 24, wherein the antibody is PA14 (ATCC Accession No. HB-12610).

Claim 28 (new): The method of claim 23 or claim 24, wherein after treatment, the subject's HIV-1 viral load is reduced to 33% or less of the subject's HIV-1 viral load prior to administering the antibody to the subject.

Claim 29 (new): The method of claim 23 or claim 24, wherein after treatment, the subject's HIV-1 viral load is reduced to 10% or less of the subject's HIV-1 viral load prior to administering the antibody to the subject.

Claim 30 (new): The method of claim 23 or claim 24, wherein after treatment, the reduction of the subject's HIV-1 viral load is sustained for a period of time.

Claim 31 (new): The method of claim 30, wherein the period of time is at least one day.

Claim 32 (new): The method of claim 30, wherein the period of time is at least three days.

Claim 33 (new): The method of claim 30, wherein the period of time is at least seven days.--

Claim 34 (new): The method of claim 23 or claim 24, wherein the effective amount of the antibody is between about 1mg and about

50mg per kg body weight of the subject.

Claim 35 (new): The method of claim 34, wherein the effective amount of the antibody is between about 2mg and about 40mg per kg body weight of the subject.

Claim 36 (new): The method of claim 35, wherein the effective amount of the antibody is between about 3mg and about 30mg per kg body weight of the subject.

Claim 37 (new): The method of claim 36, wherein the effective amount of the antibody is between about 4mg and about 20mg per kg body weight of the subject.

Claim 38 (new): The method of claim 37, wherein the effective amount of the antibody is between about 5mg and about 10mg per kg body weight of the subject.

Claim 39 (new): The method of claim 23 or claim 24, wherein the antibody is administered at least once per day.

Claim 40 (new): The method of claim 23 or claim 24, wherein the antibody is administered daily.

Claim 41 (new): The method of claim 23 or claim 24, wherein the antibody is administered every other day.

Claim 42 (new): The method of claim 23 or claim 24, wherein the antibody is administered every 6 to 8 days.--

Claim 43 (new): The method of claim 23 or claim 24, wherein the antibody is administered weekly.

Claim 44 (new): The method of claim 23 or claim 24, wherein the antibody is administered intravenously, subcutaneously, intramuscularly, intraperitoneally, orally or topically.

Claim 45 (new): The method of claim 23 or claim 24, wherein the subject is a human being and the antibody is a humanized antibody.